Finance

Lists
ONC:NASDAQ
BeOne Medicines AG
326,77 $
+2,14%
(+6,84) 1D
330,24 $
+1,06% (+3,47)
Pre-market
Closed: 23 шіл., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ONC...
Open
320,41 $
High
330,44 $
Low
317,12 $
Mkt. cap
40,46 млрд
Avg. vol.
365,04 м.
Volume
979,00
52-wk high
385,22 $
52-wk low
253,95 $
Beta
0,49
Shares outstanding
118,57 млн
No. of employees
12 мың
Open
320,41 $
High
330,44 $
Low
317,12 $
Mkt. cap
40,46 млрд
Avg. vol.
365,04 м.
Volume
979,00
52-wk high
385,22 $
52-wk low
253,95 $
Beta
0,49
Shares outstanding
118,57 млн
No. of employees
12 мың
News stories
From sources across the web
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market. BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12 мың
Founded2010 ж. 28 қаз.
Headquarters-
Sector-
Websitebeonemedicines.com
Analyst ratings
Based on 13 analysts giving stock ratings to ONC in the past 3 months
Strong buy
Buy
13
Hold
0
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for ONC in the last 3 months.
Highest
Current 326,77 $
453,00 $ (+38,63%)
Average
405,11 $ (+23,97%)
Lowest
340,00 $ (+4,05%)
Analyst
Recommendation
Action
Price target
Projected
Date
Sean Laaman
Morgan Stanley
Buy
Maintained
395,00 $
+20,9%
07/23/2026
Jessica Fye
J.P. Morgan
Buy
Maintained
425,00 $
+30,1%
07/23/2026
Etzer Darout
Barclays
Buy
Maintained
403,00 $
+23,3%
07/14/2026
Faisal Khurshid
Jefferies
Buy
Upgraded
380,00 $
+16,3%
07/12/2026
Gregory Renza
Truist Financial
Buy
Maintained
416,00 $
+27,3%
07/07/2026
Leonid Timashev
RBC Capital
Buy
Maintained
451,00 $
+38%
07/07/2026
Kalpit Patel
Wolfe Research
Buy
Maintained
340,00 $
+4%
07/01/2026
Michael Schmidt
Guggenheim
Buy
Maintained
420,00 $
+28,5%
06/15/2026
Yigal Nochomovitz
Citi
Buy
Maintained
453,00 $
+38,6%
06/12/2026
Yaron Werber
TD Cowen
Buy
Reiterated
424,00 $
+29,8%
06/02/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
415,00 $
+27%
05/20/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
367,00 $
+12,3%
05/15/2026
Jill Wu
CMB International Securities
Buy
Maintained
392,43 $
+20,1%
05/07/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
400,00 $
+22,4%
05/07/2026
Rebecca Liang
Bernstein
Buy
Maintained
412,00 $
+26,1%
03/18/2026
Next call 12 күннен кейін
5 там., ср, 14:00
Fiscal period
Q2 2026
EPS / Est. (USD)
- / 1,59 $
Revenue / Est. (USD)
- / 1,61 млрд
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025 ж. мау.
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
Revenue
1,32 млрд
1,41 млрд
1,50 млрд
1,51 млрд
Cost of goods sold
164,61 млн
196,51 млн
142,42 млн
167,22 млн
Cost of revenue
164,61 млн
196,51 млн
142,42 млн
167,22 млн
Research and development expenses
524,90 млн
523,66 млн
615,42 млн
541,22 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
537,91 млн
529,00 млн
555,29 млн
555,10 млн
Operating expense
1,06 млрд
1,05 млрд
1,17 млрд
1,10 млрд
Total operating expenses
1,23 млрд
1,25 млрд
1,31 млрд
1,26 млрд
Operating income
87,88 млн
163,11 млн
185,04 млн
249,90 млн
Other non operating income
13,19 млн
-4,76 млн
4,16 млн
14,54 млн
EBT including unusual items
99,55 млн
147,16 млн
149,24 млн
259,22 млн
EBT excluding unusual items
102,67 млн
160,80 млн
189,96 млн
259,22 млн
Income tax expense
5,23 млн
22,32 млн
82,74 млн
31,86 млн
Effective tax rate
5,25%
15,17%
55,44%
12,29%
Other operating expenses
-
-
-
-
Net income
94,32 млн
124,84 млн
66,50 млн
227,36 млн
Net profit margin
7,17%
8,84%
4,44%
15,02%
Earnings per share
0,84
1,09
0,58
1,96
Interest and investment income
11,49 млн
13,79 млн
32,37 млн
27,66 млн
Interest expense
-7,99 млн
-10,76 млн
-32,47 млн
-32,89 млн
Net interest expenses
3,50 млн
3,03 млн
-103,00 м.
-5,22 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
117,75 млн
198,86 млн
219,47 млн
289,30 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer